OKYO Pharma Limited (NASDAQ:OKYO – Get Free Report) shares traded down 1% during mid-day trading on Wednesday . The company traded as low as $1.03 and last traded at $1.04. 12,750 shares traded hands during trading, a decline of 90% from the average session volume of 123,111 shares. The stock had previously closed at $1.05.
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of OKYO Pharma in a research report on Thursday, October 24th.
OKYO Pharma Price Performance
OKYO Pharma Company Profile
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
Further Reading
- Five stocks we like better than OKYO Pharma
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 Penny Stocks Ready to Break Out in 2025
- P/E Ratio Calculation: How to Assess Stocks
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.